About this trial
The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are:
* Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate? * Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer.
Participants will:
* Receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to T3 * Visit the clinic once every week for checkups and tests * Keep a diary of their symptoms
Eligibility criteria
Qualifiers
Histologically confirmed esophageal squamous cell carcinoma
Tumor or lymph nodes invade adjacent organs (T4 stage)
Aged between 18-70 years old
Patient health status score Eastern Cooperative Oncology Group (ECOG) performance status (PS) <2
Disqualifiers
Previous chemotherapy history
Myocardial infarction within the last three months
History of unstable angina, interstitial pneumonia, fibrotic lung disease, or severe emphysema
Has other malignancies currently
Trial design
Treatments tested in this trial
- "Docetaxel", "Cisplatin", "fluorouracil", "Radiation"